Phathom Pharmaceuticals Inc is a biopharmaceutical company based in Florham Park, New Jersey, dedicated to creating treatments for gastrointestinal diseases. It specializes in a novel acid blocker, vonoprazan, aimed at managing conditions like erosive gastroesophageal reflux disease and Helicobacter pylori infections. With rights in the U.S., Europe, and Canada, Phathom is at the forefront of addressing unmet medical needs in digestive health since its founding in 2018.
Barclays analyst Jenna Davidner upgraded Phathom Pharmaceuticals (NASDAQ:PHAT) to Overweight from Equal Weight on Friday, raising her price target to $18 from $16. With the stock trading at $10.69 — down nearly…
Joel South 